Skip to content

Search

Showing results for "Childhood interstitial lung disease "

Investigating the relationship between environmental factors and respiratory health outcomes in school children using the forced oscillation technique

The significance of both indoor and outdoor sources of air pollution and effect modifiers such as green space and heating require further investigation

Respiratory impedance and bronchodilator responsiveness in healthy children aged 2-13 years

There is limited information on changes in FOT outcomes in healthy children beyond the preschool years and the level of bronchodilator responsiveness (BDR)...

Expiratory flow limitation and breathing strategies in overweight adolescents during submaximal exercise

Young people who are overweight/obese are more likely to display expFL during submaximal exercise compared with children of healthy weight.

Pulmonary diffusing capacity in healthy Caucasian children

Previous studies of pulmonary diffusing capacity in children differed greatly in methodologies; numbers of subjects evaluated, and were performed prior to...

Could Perth lakes hold the key to fighting antibiotic-resistant superbugs?

Perth researchers discovered a naturally occurring virus living in the city’s waterways that could potentially fight antibiotic-resistant superbugs.

Which reference equation should we use for interpreting spirometry values for First Nations Australians? A cross-sectional study

To evaluate the suitability of the Global Lung Function Initiative (GLI)-2012 other/mixed and GLI-2022 global reference equations for evaluating the respiratory capacity of First Nations Australians. 

Researchers share in almost $3 million for groundbreaking child health research

Five researchers from The Kids Research Institute Australia will share in almost $3 million in grants to continue groundbreaking research to tackle childhood cancer, asthma prevention, lung disease and chronic ear infections.

Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in Australia

Australia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023. 

Same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (the QuickStart Study): A cluster randomised cross-over trial protocol

Despite universal access to government-funded direct-acting antivirals in 2016, the rate of hepatitis C treatment uptake in Australia has declined substantially. Most hepatitis C is related to injecting drug use; reducing the hepatitis C burden among people who inject drugs is, therefore, paramount to reach hepatitis C elimination targets. 

Bridging the gaps in test interpretation of SARS-CoV-2 through Bayesian network modelling

In the absence of an established gold standard, an understanding of the testing cycle from individual exposure to test outcome report is required to guide the correct interpretation of SARS-CoV-2 reverse transcriptase real-time polymerase chain reaction (RT-PCR) results and optimise the testing processes.